drugset / Trial / NCT04736810
A Study of Penpulimab Combination Therapy in Patients With Advanced Nasopharyngeal Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
This is a multi-center, randomized, open-label, phase II study to evaluate the efficacy and safety of anti-PD-1 antibody Penpulimab (AK105) combined with chemotherapy ± anlotinib hydrochloride in the first-line treatment of patients with advanced nasopharyngeal carcinoma.
Timeline
- Start
- 2021-02-25
- Primary completion
- 2022-06-09
- Completion
- 2023-12-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catequentinib | Small molecule | — | Oral |
| Subject | Cisplatin | Other / unclassified | — | Intravenous |
| Subject | Gemcitabine | Small molecule | — | Intravenous |
| Subject | Penpulimab | Monoclonal antibody | — | Intravenous |